ESMO 2016 Coverage
First-line treatment with nivolumab was not superior to investigator's choice of platinum-based doublet chemotherapy for progression-free survival.
Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.
Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.
Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.
Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.
Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.
Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.
A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.
Study findings suggest that anti-PD1 immunotherapy may have significant activity among patients with early stage NSCLC.
Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.
Aurora kinase A inhibition with alisertib monotherapy may benefit a subset of patients with neuroendocrine prostate cancer (NEPC).
Among women with HER2-negative breast cancer, treatment with abemaciclib reduced Ki67 levels more than anastrozole.
Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.
Second-line treatment with nivolumab was well tolerated and associated with encouraging preliminary activity among patients with hepatocellular carcinoma.
Everolimus plus letrozole is efficacious as a first-line treatment regimen for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
Compared with best supportive care, trabectedin significantly improves progression-free survival among patients with pretreated advanced soft tissue sarcoma.
Among patients with advanced soft tissue sarcoma, adding evofosfamide to doxorubicin failed to improve overall survival compared with doxorubicin alone.
Ceritinib induced robust whole body responses in anaplastic lymphoma kinase (ALK) inhibitor-naive patients with ALK-rearranged non-small cell lung cancer (NSCLC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Bladder-sparing Therapy Outcomes Similar to Cystectomy in Bladder Cancer
- Prostate Cancer Risk and Fruit Intake
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer
- Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer
- Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results
- Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer
- Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD
- Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL